Pediatric Urology Fall Congress, Sept 9-11 2016, Fairmont The Queen Elizabeth
 Montréal, Canada



Back to 2016 Fall Congress


A case control analysis to investigate the risk factors and outcomes for neonatal nephrocalcinosis and neonatal renal calculi in neonates
Melissa J. Huynh, M.D., Roderick K. Clark, M.D., Jenny Li, M.D., Guido Filler, M.D., Sumit Dave, M.D..
Western University, London, ON, Canada.

Background: Neonatal nephrocalcinosis (NC) and renal calculi (RC) are rare and the current literature lacks studies, which compare risk factors and outcomes between cases and controls. This study uses a case-control analysis to identify risk factors for NC/RC and assesses outcomes in these neonates.
Methods: After obtaining ethics approval, we performed a case-control analysis using the neonatal intensive care (NICU) database to identify all cases of NC/RC in infants between January 2002 and December 2014 diagnosed on ultrasound (US) within the first year of life. Age- and gender- matched controls were selected from the same database who had undergone US imaging during the same time period. We assessed the following risk factors in our 2 groups: prematurity (gestational age < 37 weeks), low birth weight (< 2500 g), small for gestational age (<10th percentile weight), use of nephrotoxic drugs, respiratory factors (duration of ventilation, oxygen requirements, surfactant, antenatal steroid use), total parental nutrition, any surgeries, history of UTIs, creatinine at presentation, and history of maternal hypertension. Unadjusted odds ratios were estimated for these risk factors. A Chi-square analysis was performed for binary variables, while the Mann-Whitney U test was used for continuous variables. Outcomes assessed include time to resolution of NC/RC, renal function and blood pressure at last follow-up.
Results: During the study period, there were 68,901 births and 9256 neonates admitted to the NICU. We identified 26 cases of NC (n=16) or RC (n=14), or both). Twenty-two of the 26 cases had corresponding gender- and age-matched controls. Previous history of UTIs was the only variable that was significantly associated with the presence of NC/RC (OR 5.62, 95% CI [1.12, 31.1] p <0.013) (Table 1). At a median follow-up time of 28 months (range 0-122), there was no difference in the incidence of hypertension between the two groups (OR 2.94, 95% CI [0.40, 33.82], p=0.216). Thirteen (59.1%) patients in the NC/RC group received medical treatment. Of these, 6 received hydrochlorathiazide, 11 received citrate-based therapy, and 4 received both. Sixteen (72.7%) patients in the NC/RC group had resolution documented on ultrasound, with a median time of 12.1 months to resolution (range 0.5-50). The remainder had ongoing radiographic evidence of nephrocalcinosis or renal calculi at the end of the study period. The mean urinary calcium/creatinine ratio for the NC/RC group was <2.3±1.5 at diagnosis and <0.96±0.8 at last follow-up. There was no significant difference in creatinine at diagnosis or at last follow-up between the 2 groups.
Conclusion:
The majority of NC/RC in neonates resolve spontaneously with medical therapy without surgical intervention. The mean time to resolution is 12.1 months, without overt long-term renal consequences. The only risk factor predisposing to NC/RC was a previous history of UTIs. This study was limited by the small number of patients like other studies in the literature. Therefore, larger prospective studies, involving multiple centers are warranted to confirm these findings.
Table 1. Demographic characteristics of study population
Controls (n=22)Cases (n=22)OR (95% CI)P-value
Female gender9 (40.9%)8 (36.3%)1.21 (0.30-4.85)0.756
Birth weight (median, grams) (IQR)1830 (970-3100)1984 (1045-2610)--0.779
Gestational age at birth (median, days)236.5 (189-266)236.5 (189-267)--0.971
Low birth weight (<2500 g)13 (59.0%)15 (68.1%)1.48 (0.36-6.130.530
Prematurity (<37 weeks)13 (59.0%)13 (59.0%)1.01.0
Small for gestational age (<10th percentile)8 (36.3)6(27.2)0.65 (0.14-2.81)0.517
Multiple gestation6 (27.2)6 (27.2)0.81 (0.17-3.88)0.762
Ventilator support (median, days) (IQR)2 (0-38)2.5 (0-28)--0.883
Continuous positive airway pressure (median, days) (IQR)0 (0-6)1 (0-15)--0.508
Oxygen (median, days) (IQR)1.5 (0-70)5 (0-70)--0.660
Surfactant exposure6 (27.2)9 (40.9)2.04 (0.47-9.16)0.275
Previous urinary tract infection4 (18.1)10 (45.4)5.62 (1.12-31.1)0.013
Nephrotoxic drug exposure15 (68.1)16 (72.7)1.24 (0.28-5.61)0.741
Furosemide exposure6 (27.2)11 (50.0%)2.66 (0.64-11.62)0.121
Hydrochlorathiazide/Spironolactone exposure1 (4.5%)4 (18.1%)4.66 (0.399-240.50)0.154
Aminoglycoside exposure11 (50.0%)14 (81.8%)1.75 (0.44-6.42)0.361
Vancomycin exposure11 (50.0%)10 (45.4)0.83 (0.21-3.18)0.762
Meropenem exposure6 (27.2)1 (4.5%)0.12 (0.002-1.25)0.393
Indocid/Nonsteroidal anti-inflammatory drug exposure6 (27.2)6 (27.2)1.0 (0.21-4.65)1.0
Total parenteral nutrition14 (81.8%)15 (68.1)1.22 (0.29-5.31)0.750
Maternal hypertension8 (36.3%)6 (27.2)1.37 (0.25-7.41)0.667
Previous surgery14 (81.8%)9 (40.9%)0.39 (0.09-1.55)0.131


Back to 2016 Fall Congress